Robert Sachs filed this petition with DoD, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by Astellas. The petition asks that that march-in be granted on the grounds that charging significantly higher prices in the United States than in other high income countries is not consistent with the obligation to make the benefits of the inventions “available to the public on reasonable terms.”